JPWO2021095009A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021095009A5 JPWO2021095009A5 JP2022527744A JP2022527744A JPWO2021095009A5 JP WO2021095009 A5 JPWO2021095009 A5 JP WO2021095009A5 JP 2022527744 A JP2022527744 A JP 2022527744A JP 2022527744 A JP2022527744 A JP 2022527744A JP WO2021095009 A5 JPWO2021095009 A5 JP WO2021095009A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- human patient
- pharmaceutical composition
- dose
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934945P | 2019-11-13 | 2019-11-13 | |
| US62/934,945 | 2019-11-13 | ||
| US202063034510P | 2020-06-04 | 2020-06-04 | |
| US63/034,510 | 2020-06-04 | ||
| PCT/IB2020/060718 WO2021095009A1 (fr) | 2019-11-13 | 2020-11-13 | Thérapie pour les malignités des cellules hématopoïétiques utilisant des lymphocytes t génétiquement modifiés ciblant cd70 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501590A JP2023501590A (ja) | 2023-01-18 |
| JPWO2021095009A5 true JPWO2021095009A5 (fr) | 2023-11-06 |
Family
ID=73554470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527744A Pending JP2023501590A (ja) | 2019-11-13 | 2020-11-13 | Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用する造血細胞悪性腫瘍のための療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220387571A1 (fr) |
| EP (1) | EP4058051A1 (fr) |
| JP (1) | JP2023501590A (fr) |
| KR (1) | KR20220100912A (fr) |
| CN (1) | CN114845730A (fr) |
| AU (1) | AU2020384951A1 (fr) |
| BR (1) | BR112022009290A2 (fr) |
| CA (1) | CA3158090A1 (fr) |
| IL (1) | IL292467A (fr) |
| MX (1) | MX2022005815A (fr) |
| WO (1) | WO2021095009A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022015586A (es) | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| US20220387488A1 (en) * | 2021-05-12 | 2022-12-08 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
| US20230128917A1 (en) * | 2021-09-14 | 2023-04-27 | Crispr Therapeutics Ag | Genetically engineered immune cells having a disrupted cd83 gene |
| CN117173092B (zh) * | 2023-06-28 | 2024-04-09 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种基于图像处理的鼻咽癌放疗方法及系统 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3481861B1 (fr) * | 2016-07-06 | 2024-07-31 | Cellectis | Édition de gènes séquentielle dans des cellules immunitaires primaires |
| US20180325955A1 (en) * | 2017-05-12 | 2018-11-15 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| EP3746483A1 (fr) * | 2018-02-01 | 2020-12-09 | Pfizer Inc | Récepteurs antigéniques chimériques ciblant cd70 |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
-
2020
- 2020-11-13 KR KR1020227019519A patent/KR20220100912A/ko unknown
- 2020-11-13 CN CN202080086735.4A patent/CN114845730A/zh active Pending
- 2020-11-13 CA CA3158090A patent/CA3158090A1/fr active Pending
- 2020-11-13 IL IL292467A patent/IL292467A/en unknown
- 2020-11-13 US US17/776,846 patent/US20220387571A1/en active Pending
- 2020-11-13 MX MX2022005815A patent/MX2022005815A/es unknown
- 2020-11-13 JP JP2022527744A patent/JP2023501590A/ja active Pending
- 2020-11-13 AU AU2020384951A patent/AU2020384951A1/en not_active Abandoned
- 2020-11-13 BR BR112022009290A patent/BR112022009290A2/pt not_active Application Discontinuation
- 2020-11-13 EP EP20812137.6A patent/EP4058051A1/fr not_active Withdrawn
- 2020-11-13 WO PCT/IB2020/060718 patent/WO2021095009A1/fr active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lamb et al. | Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future | |
| JP6963051B2 (ja) | 免疫療法のための組成物および方法 | |
| Hay et al. | Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell malignancies | |
| JP6767347B2 (ja) | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 | |
| Kuzel et al. | Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma | |
| ES2835232T3 (es) | CART19 para la utilización en un método de reducción del número de células B normales para la inducción de tolerancia | |
| ES2692206T3 (es) | Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades | |
| Song et al. | IL‐12/IL‐18‐preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation | |
| WO2017189526A1 (fr) | Cellules immunitaires à expression cd26 élevée et cellules immunes cd26-négatives activées et leurs utilisations | |
| JPH09510456A (ja) | 同種リンパ球による癌の免疫療法 | |
| Shimizu et al. | Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2 | |
| Alvarez‐Fernández et al. | Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma | |
| CN110404061B (zh) | 改进的t细胞治疗方法 | |
| Inamoto et al. | A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation | |
| Miljkovic et al. | Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies | |
| JPWO2021095009A5 (fr) | ||
| CA2098720C (fr) | Composition cellulaire pour le traitement des organismes humains ou animaux | |
| George et al. | Emerging targets and cellular therapy for relapsed refractory multiple myeloma: a systematic review | |
| Ruiz-Argüelles et al. | Extramedullary leukemic relapses following hematopoietic stem cell transplantation with nonmyeloablative conditioning | |
| JP3541950B2 (ja) | 癌およびウイルス性疾患を治療するための改変化ｔａｌｌ−１０４細胞の使用 | |
| Schiltz et al. | Effects of IFN-γ and interleukin-1 β on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes | |
| JPWO2021095010A5 (fr) | ||
| Atilla et al. | Are we there yet? cellular therapies for cutaneous T cell lymphoma | |
| JPWO2021095011A5 (fr) | ||
| Jaime-Ramirez et al. | NK cell–mediated antitumor effects of a folate-conjugated immunoglobulin are enhanced by cytokines |